AGC's Japanese and Danish factories to produce German biotech firm's drug candidate

German 4teen4 has chosen AGC Biologics as contract developer for the clinical testing of its drug candidate, procizumab.

In August, AGC broke ground on an expansion of its factory in Hillerød, Copenhagen | Photo: AGC Biologics / PR

Contract manufacturing organization AGC Biologics has entered into a partnership with biotech company 4teen4 Pharmaceuticals to produce the latter firm's drug candidate, procizumab, according to an AGC press release.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs